Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.61 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7451658 | 1.00 | TRPA1 (0.61) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL7451666 | 1.00 | TRPA1 (0.61) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL11439697 | 0.98 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL2416574 | 0.98 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL31303623 | 0.98 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL12300774 | 0.98 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL10675600 | 0.98 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL8907239 | 0.98 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL11439694 | 0.98 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTACHE | |
| SCHEMBL2416572 | 0.98 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201620-A | Inhaled iloprost for on-demand treatment of pulmonary arterial hypertension | 尤斯图斯-李比希大学 | 2024-06-14 | — | — | CN | disclosed |
| US-20140377337-A1 | TRANSDERMAL APPLICATION OF PROSTAGLANDIN E1 FOR THE TREATMENT OF OCULAR ISCHEMIA | STEIGERWALT JR ROBERT DAVIS (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2013114418-A1 | TRANSDERMAL ADMINISTRATION OF PROSTAGLANDIN E1 FOR THE TREATMENT OF OCULAR ISCHEMIA | STEIGERWALT ROBERT DAVIS JR (IT) | 2013-08-08 | — | — | WO | disclosed |
| EP-1481976-B1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8198315-B2 | Therapeutic substituted cyclic lactams | ALLERGAN, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7683094-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7683094-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7402605-B2 | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-7402605-B2 | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | TRPA1 1811/4885DDAH1 3384/4885GAPDH 1142/4885 |
| US-20140377337-A1 | TRANSDERMAL APPLICATION OF PROSTAGLANDIN E1 FOR THE TREATMENT OF OCULAR ISCHEMIA | PTGER1, PTGS1, PTGES | TRPA1 333/4885DDAH1 3404/4885GAPDH 1185/4885 |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | TRPA1 1811/4885DDAH1 3384/4885GAPDH 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.